STAT3 Therapeutics is an early stage oncology-focused company, dedicated to developing and commercializing drugs that target the activated STAT3 molecule. Their unique approach arrests the activity of the STAT3 dimer using a cyclic decoy that binds to the molecule in a way that is both specific and impactful, without significant toxic side effects.